Search

Your search keyword '"Gambacciani M"' showing total 587 results
Start Over Author "Gambacciani M"
587 results on '"Gambacciani M"'

1. Contraception with estradiol valerate and dienogest: adherence to the method

Author

Fruzzetti F, Paoletti AM, Fidecicchi T, Posar G, Giannini R, and Gambacciani M

Subjects
Estradiol valerate, hormonal contraceptives, irregular bleedings, dienogest, Gynecology and obstetrics, RG1-991
Abstract

Franca Fruzzetti,1 Anna Maria Paoletti,2 Tiziana Fidecicchi,1 Giulia Posar,1 Riccardo Giannini,3 Marco Gambacciani11Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy; 2Department of Obstetrics and Gynecology, Cagliari University Hospital, Cagliari, Italy; 3Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, ItalyPurpose: The aim of the study was to examine the discontinuation rate of hormonal contraception with estradiol valerate (E2V) and dienogest (DNG).Patients and methods: We collected data at the Family Planning Clinics of the Departments of Obstetrics and Gynecology of Pisa and Cagliari. We included in the analysis 354 consecutive women using oral contraceptive pills containing E2V and DNG. We analyzed the rate and the reason for discontinuation, classifying the reasons in 5 categories: 1) minor side effects, 2) adverse events, 3) other events not directly caused by the drug or conditions for which the pill could represent a risk factor, 4) no compliance with the method and 5) no further need.Results: Of the 354 women examined, 50.8% had discontinued E2V/DNG pill. Excluding women who stopped the pill because of no further need (10.5%), 27.4% discontinued because of minor side effects, 1.7% discontinued for adverse events, 9.9% because of other events not directly caused by the drug or conditions for which the pill could represent a risk factor and 1.4% because of difficulties with compliance. Irregular bleedings were the main reasons reported for discontinuation. The time to discontinuation for irregular bleedings was significantly (p

Published
2019

7. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society

Author

Lambrinoudaki, I. Armeni, E. Goulis, D. Bretz, S. Ceausu, I. Durmusoglu, F. Erkkola, R. Fistonic, I. Gambacciani, M. Geukes, M. Hamoda, H. Hartley, C. Hirschberg, A.L. Meczekalski, B. Mendoza, N. Mueck, A. Smetnik, A. Stute, P. van Trotsenburg, M. Rees, M.

Abstract

This care pathway from the European Menopause and Andropause Society (EMAS) provides an updated pathway for monitoring and guidance of women at midlife, focusing on those approaching the end of the reproductive life-cycle, going through the menopausal transition and beyond. The care pathway is written by professionals involved in women's health and provides a stepwise individualized approach, stratified according to needs, symptoms and reproductive stage. Furthermore, the pathway provides details on screening for chronic diseases related to menopause and ageing. Treatment options for climacteric symptoms range from menopausal hormone therapy to non-hormonal alternatives and lifestyle modifications. Therapy should be tailored to personal needs and wishes. The pathway aims to offer a holistic, balanced approach for monitoring middle-aged women, aiming to control health problems effectively and ensure healthy ageing. © 2022 Elsevier B.V.

Published
2022

8. Phytotherapy for menopausal symptoms: Recommendations of the italian menopause society (SIM) and the Italian society of gynaecology for the third age (SIGiTE)

Author

Cagnacci A., Volpe A., Di Carlo C., De Leo V., Bifulco G., Gambacciani M., Alfieri S., Biglia N., Bonaccorsi G., Caruso S., Cicinelli E., De Franciscis P., Gambera A., Grasso A., Murina F., Paoletti A. M., Vicariotto F., Villa P., Gallo M., Nocera F., Maffei S., Pandolfo M., Lello S., Ambroggio S., Capozzi A., Grassi G., Rossi R., Stomatis M., Becorpi A., Forte A., Azzena A., Costantino D., Del Pup L., Mapelli M., Cagnacci, A., Volpe, A., Di Carlo, C., De Leo, V., Bifulco, G., Gambacciani, M., Alfieri, S., Biglia, N., Bonaccorsi, G., Caruso, S., Cicinelli, E., De Franciscis, P., Gambera, A., Grasso, A., Murina, F., Paoletti, A. M., Vicariotto, F., Villa, P., Gallo, M., Nocera, F., Maffei, S., Pandolfo, M., Lello, S., Ambroggio, S., Capozzi, A., Grassi, G., Rossi, R., Stomatis, M., Becorpi, A., Forte, A., Azzena, A., Costantino, D., Del Pup, L., and Mapelli, M.

Subjects
genistein, Cimicifuga racemosa, pollen extract, Daidzein, Equol, Genistein, Hot flush, Phytoestrogens, Pollen extract, LS4_1, Phytoestrogens, genistein, daidzein, equol, pollen extract, Cimicifuga racemosa, hot flush, hot flush, Menopause, Phytoestrogen, Cimicifuga Racemosa, daidzein, NO, equol
Abstract

Evidence on the efficacy of phythotherapic remedies for the treatment of menopausal symptoms were reviewed. Evidence of the literature were graded and level of reccomandation defined. A strenght A recommendation was given for isaproponol extract of Cimicifuga recemosa (systematic review and metanalysis). Strength B recommendation, due to some inconsistent findings or lower quality studies, was given to the use of soy isoflavones, genistein above 30 mg/day, equol containing product and pollen extract. Strength C reccomendation for very weak evidence of efficacy was given to resveratrol, hops, dioscorea, enotera. No evidence of efficacy on vasomotor symptoms was found for Hyperycum perforatum, matcha, ginseng, that find no place in the treatment of vasomotor symptoms.

Published
2021

10. Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence

Author

Castelo-Branco C, Gambacciani M, Cano A, Minkin M, Rachon D, Ruan X, Beer A, Schnitker J, Henneicke-von Zepelin H, and Pickartz S

Subjects
safety, meta-analysis, Cimicifuga racemosa, evidence, animal diseases, isopropanolic extract, menopausal symptoms, efficacy, Actaea racemosa, virus diseases, black cohosh
Abstract

A systematic literature search revealed 35 clinical studies and one meta-analysis comprising 43,759 women, of which 13,096 were treated with isopropanolicCimicifuga racemosaextract (iCR). Compared to placebo, iCR was significantly superior for treating neurovegetative and psychological menopausal symptoms, with a standardized mean difference of -0.694 in favor of iCR (p < 0.0001). Effect sizes were larger when higher dosages of iCR as monotherapy or in combination with St. John's wort (Hypericum perforatum[HP]) were given (-1.020 and -0.999, respectively), suggesting a dose-dependency. For psychological symptoms, the iCR+HP combination was superior to iCR monotherapy. Efficacy of iCR was comparable to low-dose transdermal estradiol or tibolone. Yet, due to its better tolerability, iCR had a significantly better benefit-risk profile than tibolone. Treatment with iCR/iCR+HP was well tolerated with few minor adverse events, with a frequency comparable to placebo. The clinical data did not reveal any evidence of hepatotoxicity. Hormone levels remained unchanged and estrogen-sensitive tissues (e.g. breast, endometrium) were unaffected by iCR treatment. As benefits clearly outweigh risks, iCR/iCR+HP should be recommended as an evidence-based treatment option for natural climacteric symptoms. With its good safety profile in general and at estrogen-sensitive organs, iCR as a non-hormonal herbal therapy can also be used in patients with hormone-dependent diseases who suffer from iatrogenic climacteric symptoms.

Published
2021

11. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?

Author

Cagnacci, A., Bonaccorsi, G., Gambacciani, M., Villa, Paola, board of the Italian Menopause Society, The, Paola Villa (ORCID:0000-0002-4402-6988), Cagnacci, A., Bonaccorsi, G., Gambacciani, M., Villa, Paola, board of the Italian Menopause Society, The, and Paola Villa (ORCID:0000-0002-4402-6988)

Abstract

Since the COVID-19 pandemic outbreak, the extent of serious complications and high rate of mortality has concerned all the health authorities worldwide. Death by COVID-19 is mainly due to acute re- spiratory distress syndrome (ARDS), although heart and multiple organ failure may contribute [1]. Underlying mechanisms are COVID-19-in- duced endothelial alteration, cytokine storm, inflammation, exudation in the lungs, and vessel occlusion.

Published
2020

12. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?

Author

Cagnacci, A, Bonaccorsi, G, Gambacciani, M, Villa, Paola, of the Italian Menopause Society, Board, P. Villa (ORCID:0000-0002-4402-6988), Cagnacci, A, Bonaccorsi, G, Gambacciani, M, Villa, Paola, of the Italian Menopause Society, Board, and P. Villa (ORCID:0000-0002-4402-6988)

Abstract

Since the COVID-19 pandemic outbreak, the extent of seriouscomplications and high rate of mortality has concerned all the healthauthorities worldwide. Death by COVID-19 is mainly due to acute re-spiratorydistresssyndrome(ARDS),althoughheartandmultipleorganfailure may contribute [1]. Underlying mechanisms are COVID-19-in-duced endothelial alteration, cytokine storm, inflammation, exudationin the lungs, and vessel occlusion.1. DifferencebetweensexesMortalitybyCOVID-19ishigherinmenthaninwomen.Amongtheadvocated reasons are a different exposure to risk factors such assmoking, reduced care of men about their health or different associa-tion with other morbidities. Nevertheless, a different expression ofACE2 may explain the different mortality between sexes. COVID-19disease progression is reduced by ACE2 enzyme expression in en-dothelial cells mainly at the lung and heart, where it exerts vasodi-lating, anti-inflammatory and anticoagulant effects [2]. ACE2 is codedby the X chromosome, of which men have only one, and ACE2 ex-pression in endothelial cells is stimulated by estrogens [2]. The possi-bility that thismechanisms accountsfor the lowermortalityof womenvs. men (Yi et al.) is sustained by the recent evidence that reducedmortality (−72 %) of fertile women vs. men is lost, at least in part, inthe postmenopausal years (−49.6 %) [3].2. HormonetherapyThese data lead to speculation that hormone therapy or even po-tentiating estrogen stimulus by exogenous estrogens may antagonizethe deadly progression of the disease. On the other hand, exogenousestrogens may increase coagulating factors and the risk of throm-boembolic events with a potential consequent increase in mortality.Hospitalized individuals with very severe COVID-19 disease have anactivated coagulation defined by high levels of D-dimers, products offibrin degradation, and when D-dimer levels are very high, antic-oagulants like heparin may reduce mortality [4]. In order to decreasethe risk of thromboembolic events a r

Published
2020

13. Female sexuality and vaginal health across the menopausal age

Author

Angelo, Cagnacci, Martina, Venier, Anjeza, Xholli, Chiara, Paglietti, Salvatore, Caruso, for the ANGEL Study Group: Algeri, M, Donvito, G, Bastianelli, C, Cagnacci, A, Palma, F, Napolitano, A, Capobianco, G, Dessole, S, Cianci, A, Caruso, S, Cinque, B, Dati, S, Cioffi, Gp, Costantino, D, D’Anna, R, De Leo, V, Di Carlo, C, Di Francesco, A, Di Renzo, G, Baldoni, A, Lorefice, R, Ferrazzi, E, Valente, I, Gambacciani, M, Gambera, A, Greco, P, Bonaccorsi, G, Guaschino, S, Tredici, Z, Labanchi, R, Chiacchio, A, Lanzone, A, Villa, P, Lello, S, Capozzi, A, Leo, L, Salvatores, M, Marchesoni, D, Vogrig, E, Perrone, A, Segatore, M, Pallone, B, Petruzzelli, F, Libergoli, A, Roccamorena, A, Scarciglia, M, Serracchioli, R, Meriggiola, C, Surico, N, Zorzeti Cigna, S, Zullo, F, Delfini, R, and Giovannini, P

Subjects
Adult, medicine.medical_specialty, Cross-sectional study, General Mathematics, media_common.quotation_subject, Vaginal Diseases, 030209 endocrinology & metabolism, Human sexuality, Orgasm, NO, 03 medical and health sciences, 0302 clinical medicine, Atrophy, FSFI, Menopause, Perimenopause, Sexuality, Vaginal atrophy, Vaginal dryness, Sexuality, FSFI, Vaginal atrophy, Vaginal dryness, Menopause, Perimenopause, medicine, Prevalence, Humans, media_common, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics, Applied Mathematics, Obstetrics and Gynecology, Middle Aged, medicine.disease, Sexual Dysfunction, Physiological, Sexual dysfunction, Cross-Sectional Studies, Dyspareunia, Multicenter study, Italy, Vagina, FSFI, Menopause, Perimenopause, Sexuality, Vaginal atrophy, Vaginal dryness, Observational study, Female, medicine.symptom, business
Abstract

The primary aim was to evaluate changes in female sexuality across the menopausal period, and the secondary objective was to test the associations of female sexuality domains with vaginal atrophy and its symptoms.A cross-sectional multicenter study was performed involving 518 women, 40 to 55 years of age, consulting outpatient gynecological services at 30 centers across Italy. Vaginal atrophy was identified by the contemporaneous presence of a pH5, subjective vaginal dryness, and an objective sign. The relationships between vaginal atrophy and its main symptoms (vaginal dryness and dyspareunia), and Female Sexual Function Index (FSFI) score and its domains (desire, arousal, orgasm, dyspareunia, lubrication, and sexual satisfaction) were analyzed.The prevalence of sexual dysfunction, as defined by a FSFI score26.55, was 70.6%, increasing from 55% in the years 40 to 45, to 82.8% (P 0.01) in the years 52 to 55 of age. Mean FSFI score decreased from 40 to 45, to 46 to 48 years of age (23.13 ± 9.76 vs 19.49 ± 9.88; P 0.05), and from 48 to 51, to 52 to 55 years of age (21.3 ± 8.06 to 17.59 ± 9.11; P 0.01). Independent determinants of FSFI were age, vaginal atrophy, and the presence of vaginal dryness and dyspareunia (R2 0.208; P = 0.011). FSFI score was independently correlated (R2 0.116) with weight (CR -0.067; 95% confidence interval [CI] -0.126, -0.006; P 0.032), menopausal status (CR -2.406; 95% CI -4.180, -0.63; P 0.008), and vaginal dryness (CR -5.647; 95% CI -7.677, -3.618; P 0.0001). Vaginal dryness was the only variable correlated independently with each FSFI domain, including desire (also correlated with menopausal status), arousal (with age and menopausal status), lubrication (with age), orgasm (with age), satisfaction (with vaginal atrophy and being an ex-smoker), and dyspareunia (with age and spontaneously referred dyspareunia).In the perimenopausal years, FSFI score decreases and sexual dysfunction increases by about 30%. Vaginal dryness is the symptom of vaginal atrophy most closely related to all domains of female sexuality.

Published
2019

14. Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE)

Author

Cagnacci, A., Gallo, M., Gambacciani, M., Lello, S., Volpe, A, Lanzone, A, Di Carlo, C, De Leo, V, Biglia, N, Caruso, S, Cicinelli, E, Farris, M, Gambera, A, Guaschino, S, Paoletti, Am, Russo, N, Vicariotto, F, Villa, P, Nocera, F, Maffei, S, Pandolfo, M, Ambroggio, S, Grassi, G, De Seta, F, Stomati, M, Gullo, D, Becorpi, A, Cancellieri, F, Fiorillo, F, Del Pup, L, Mapell, C, and Ottanelli, S.

Subjects
medicine.medical_specialty, Peri, Vaginal Diseases, Post menopausal, Guideline, 03 medical and health sciences, Therapeutic approach, 0302 clinical medicine, Quality of life, Laser therapy, Diagnosis, medicine, Humans, Physician-Patient Relations, 030219 obstetrics & reproductive medicine, Postmenopausal women, Obstetrics, business.industry, Obstetrics and Gynecology, Atrophy, Postmenopause, medicine.disease, Perimenopause, Female, Quality of Life, Vulvar Diseases, 030220 oncology & carcinogenesis, Vaginal atrophy, business
Abstract

Herein, joint recommendations for diagnosis and treatment of vulvo-vaginal atrophy (VVA) in women in the peri- and post-menopausal phases from the Societa Italiana per la Menopausa (SIM) and the Societa Italiana della Terza Eta (SIGiTE) are presented. The recommendations are aimed at all healthcare personnel caring for women in the menopausal transition or postmenopausal phase, and are also intended to raise awareness of VVA. Recent data clearly indicate VVA is a highly prevalent condition among postmenopausal women, and that the vast majority of women with VVA are not adequately treated. In reality, diagnosis of VVA is simple and largely clinical. Many types of treatments are available for VVA, ranging from preventive education measures to local non-hormonal therapies, local agents that modulate hormonal receptors and systemic as well as laser therapy and radiofrequency. Regardless of the therapeutic approach adopted, greater communication between the physician and the woman with VVA should be actively encouraged. This is also in light of the difficulty of talking about the VVA and related disorders. Greater communication also encourages adequate therapy and thus minimizes the impact of VVA on the quality of life of the woman and her partner.

Published
2019

20. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?

Author

Cagnacci, A., primary, Bonaccorsi, G., additional, Gambacciani, M., additional, De Leo, V., additional, Di Carlo, C., additional, Bifulco, G., additional, Alfieri, S., additional, Biglia, N., additional, Caruso, S., additional, Cicinelli, E., additional, De Franciscis, P., additional, Gambera, A., additional, Grasso, A., additional, Murina, F., additional, Paoletti, A.M., additional, Vicariotto, F., additional, Villa, P., additional, and Volpe, A., additional

Published
2020
Full Text
View/download PDF

24. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women

Author

Nick, Panaya, Santiago, Palacios, Nico, Bruyniks, Martire, Particco, Nappi, Rossella E., Argudo, Prieto, Baqueda, L., Becorpi, A. M., Benedetti Panici, P., Benedetto, C., Biglia, N., Busacca, M., Cagnacci, A., Calleja Abu-Amshah, J., Cancelo Hidalgo, M. J., Castelo Branco i Flores, C., Cianci, A., Cicinelli, E., Coronado Martin, P., Correa Rancel, M., De Seta, F., Di Carlo, C., Fernández Abellán, M., Fernández Moya, J. M., Gambacciani, M., García Alfaro, P., González Fernández, M., González Rodríguez, S., Guida, M., Iglesias Bravo, E., Llaneza Coto, P., Luisi, S., Manubens Grau, M., Marchesoni, D., Marín Sánchez, P., Mendoza Ladrón de Guevara, N., Nappi, R., Otero García- Ramos, B., Paoletti, A. M., Palacios, S., Pellegrino, A., Presa Lorite, J. C., Remorgida, V., Salvatore, S., Sánchez Borrego, R., Sánchez Méndez, S., Seracchioli, R., Stomati, M., Surico, N., Vázquez Fernández, F., and P. Villa.

Subjects
Quality of life, medicine.medical_specialty, Hormone Replacement Therapy, Cross-sectional study, Sexual Behavior, Sexual function, medicine.medical_treatment, Severity of Illness Index, General Biochemistry, Genetics and Molecular Biology, Vulva, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, Internal medicine, Severity of illness, Non-hormonal treatment, medicine, Humans, 030212 general & internal medicine, Aged, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics and Gynecology, Hormone replacement therapy (menopause), Middle Aged, Postmenopause, Distress, Cross-Sectional Studies, Dyspareunia, Treatment Outcome, Settore MED/40 - GINECOLOGIA E OSTETRICIA, medicine.anatomical_structure, Vagina, Vulvovaginal atrophy, Female, Hormonal treatment, Atrophy, Symptom Assessment, business
Abstract

To evaluate the association between treatments for vulvovaginal atrophy (VVA) and symptom frequency and severity, quality of life (QoL) and sexual functioning in postmenopausal women.Cross-sectional survey conducted in postmenopausal women aged 45-75 years. Data on demographic and clinical variables, as well as vaginal, vulvar and urinary symptoms were collected. The EuroQoL questionnaire (EQ5D3L), the Day-to-Day Impact of Vaginal Aging (DIVA), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale - revised (FSDS-R) were filled out.Association between treatments for VVA and symptom frequency.Women on VVA treatment presented with more severe symptoms. The sexual function score was higher in the treated women (FSFI: 15.6 vs 16.7; p = 0.010), as was the score for sexual distress (FSDS-R: 9.2 vs 12.3, p 0.0005). The systemic hormone group presented with fewer VVA symptoms, lower vaginal impact (DIVA), and better sexual function (FSFI and FSDS-R) and vaginal health. The rates of sexual distress and vulvar atrophy were higher in the non-hormonal treatment group. No significant differences were found according to treatment duration.Postmenopausal women with VVA receiving treatment complained of more severe symptoms than those untreated. Women on systemic treatment had fewer and milder VVA symptoms and presented with better vaginal and vulvar health than women on other treatments. Many women request effective local treatment too late, when VVA symptoms are already severe. Our data suggest that VVA treatments should ideally be initiated when symptoms commence and cause distress, rather than later, when symptoms may have become more severe and even a cause of intolerable distress for the woman.

Published
2019

28. The European Vulvovaginal Epidemiological Survey (EVES) in Italy. Impact of vulvovaginal atrophy on the quality of life and sexual function in breast cancer survivors

Author

Nappi, R. E., Biglia, N., Cicinelli, E., Paolantonio, T. D., Luisi, S., Stomati, M., Villa, P., Becorpi, A. M., Benedetti Panici, P., Benedetto, C., Busacca, M., Cagnacci, A., Cianci, A., de Seta, F., Di Carlo, C., Gambacciani, M., Guida, M., Marchesoni, D., Paoletti, A. M., Palacios, S., Pellegrino, A., Remorgida, V., Salvatore, S., Seracchioli, R., and Surico, N.

Subjects
Quality of life, Gynecological examination, medicine.medical_specialty, Obstetrics, business.industry, Genitourinary syndrome of menopause, Sexual dysfunction, Obstetrics and Gynecology, Vulvovaginal atrophy, medicine.disease, Gynecological Examination, Breast cancer, Menopause, Oncology, Epidemiology, medicine, medicine.symptom, Sexual function, business
Published
2021

33. Menopausia y Terapia Hormonal de la Menopausia Las recomendaciones 2018 de la Unidad de Endocrinología Ginecológica de Clínica Alemana de Santiago -Sociedad Italiana de la Menopausia y la Sociedad Chilena de Endocrinología Ginecológica

Author

Parra, M., primary, Lagos, N., additional, Levancini, M., additional, Villarroel, M., additional, Pizarro, E., additional, Vanhauwaert, P,, additional, Velasco, S., additional, Fernadez, M, additional, Gambacciani, M., additional, Biglia, N., additional, Cagnacci, A., additional, Caruso, S., additional, Cicinelli, E., additional, Leo, V. De, additional, Carlo, C. Di, additional, Farris, M., additional, Gambera, A., additional, Guaschino, S., additional, Lanzone, A, additional, Paoletti, AM, additional, Russo, N., additional, Vicariotto, F., additional, Villa, P., additional, Volpe, A., additional, Lavin, P., additional, Lopez, M., additional, Campusano, C., additional, Barriga, P., additional, and Brantes, S., additional

Published
2018
Full Text
View/download PDF

34. Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study.

Author

Gambacciani, M., Albertin, E., Torelli, M. G., Bracco, G. L., Casagrande, A. C., Martella, L., Baiocchi, G., Alfieri, S., Russo, N., Cervigni, M., and Italian Vaginal Erbium Laser Academy

Subjects
*POSTMENOPAUSE, *LONGITUDINAL method, *LASERS, *MENOPAUSE, *LASER therapy, *RESEARCH, *MEDICAL lasers, *RESEARCH methodology, *MEDICAL cooperation, *EVALUATION research, *TREATMENT effectiveness, *COMPARATIVE studies, *GENITOURINARY diseases, *URINARY stress incontinence, VAGINAL surgery
Abstract

The aim of this multicentric, prospective study was to evaluate the effects of vaginal erbium laser (VEL-SMOOTH®) on sexual function in postmenopausal women suffering from the genitourinary syndrome of menopause (GSM). This study was performed on an outpatient basis without anesthesia or drug use before or after the intervention, using an erbium laser (XS Fotona Smooth®, Fotona, Ljubljana, Slovenia) in 1081 postmenopausal women (age 54.3 ± 3.9 years) treated with up to three laser applications every 30 days. Patients were assessed using the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R). No adverse events were recorded during the study. The FSDS-R scores (n = 554), from basal values of 25.5 ± 3.5, were 11.5 ± 3.0, 10.5 ± 3.5 and 11.5 ± 3.5 at the 4-, 12- and 24-week follow-ups, respectively (p < 0.01 vs. corresponding basal values). Individual FSFI domain scores (n = 569) significantly (p < 0.001) increased after VEL-SMOOTH® treatment and remained significantly higher up to the 24th week after the end of treatment. The total scores, from basal values of 15.5 ± 1.5, were 27.5 ± 2.5, 27.6 ± 2.7and 27.0 ± 3.5 at the 4-, 12- and 24-week follow-ups, respectively (p < 0.01 vs. corresponding basal values). Albeit not randomized, this large, prospective study shows that VEL-SMOOTH® treatment may improve sexual function in postmenopausal women suffering from GSM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. Tailored hormonal approach in women with premature ovarian insufficiency.

Author

Fruzzetti, F., Palla, G., Gambacciani, M., and Simoncini, T.

Subjects
PREMATURE ovarian failure, HORMONE therapy, PUBERTY, PREMATURE menopause
Abstract

Copyright of Climacteric is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2020
Full Text
View/download PDF

38. Assessment of the QoL in Italian menopausal women: comparison between HRT users and non-users

Author

Genazzani, A. R., Nicolucci, A., Campagnoli, C., Crosignani, P., Nappi, C., Serra, G. B., Bottiglioni, E., Cianci, A., Aloysio, D. D., Sarti, C. D., Gambacciani, M., Monteleone, P., Genazzani, Alessandro, Guaschino, S., Palumbo, G., Petraglia, F., Schonauer, S., Volpe, Annibale, Paolantonio, T. D., Nagni, M., Tempesta, A., Coronel, G. A., Qualità, P. D., Genazzani, Ar, Nicolucci, A, Campagnoli, C, Crosignani, P, Nappi, Carmine, Serra, Gb, Bottiglioni, E, Cianci, A, De Aloysio, D, Donati Sarti, C, Gambacciani, M, Monteleone, P, Genazzani, Ad, Guaschino, S, Palumbo, G, Petraglia, F, Schonauer, S, Volpe, A, Di Paolantonio, T, Nagni, M, Tempesta, A, and Coronel, Ga

Subjects
Gerontology, medicine.medical_specialty, Multivariate analysis, Psychometrics, HRT, Health Status, General Biochemistry, Genetics and Molecular Biology, Quality of life, Surveys and Questionnaires, Epidemiology, Humans, Medicine, Gynecology, Response rate (survey), business.industry, Public health, Estrogen Replacement Therapy, Female, Italy, Menopause, Middle Aged, Multivariate Analysis, Quality of Life, Questionnaires, Socioeconomic Factors, Obstetrics and Gynecology, medicine.disease, Anxiety, sense organs, medicine.symptom, business
Abstract

Objectives: The aim of this cross-sectional study was to describe QoL in a large sample of women attending menopause centres and compare untreated postmenopausal women and matched HRT users by employing the Women's Health Questionnaire (WHQ) and two generic instruments, the SF-36 and the EQ-5D. Methods: Overall, 2906 women were recruited by 64 menopause centres throughout Italy, of whom 2160 filled in the questionnaire (1093 on HRT and 1067 not on HRT; response rate: 74%). Results: HRT users tended to be younger, healthier and with shorter menopause duration as opposed to non users, while no major socio-economic differences were present. At multivariate analysis, the presence of chronic diseases, low socio-economic status and living in Southern Italy represented the most important predictors of poor QoL. Furthermore, HRT users showed a lower probability of reporting problems in usual activities and pain/discomfort (EQ-5D), role limitations due to emotional problems (SF-36) and anxiety/fears (WHQ). HRT users also showed highly significant better outcomes in those areas that are more directly attributable to hormonal changes of mid age, namely vasomotor symptoms and sexual problems. Conclusions: Although QoL is mainly influenced by socio-economic and cultural factors, HRT has the potential for improving not only symptoms, but also more general aspects of physical and psychological well-being of symptomatic postmenopausal women.

Published
2002

40. Osteoporosis's Menopausal Epidemiological Risk Observation (O.M.E.R.O.) study

Author

Lello, Stefano, Sorge, Roberto, Surico, Nicola, OMERO Study Group, Tranquilli, A, Turi, A, Agostinelli, D, Messini, S, Gambera, A, Stomati, M, Paoletti, Am, Sanna, S, Durante, M, Roccu, I, Scollo, P, Nocera, F, Ronca, E, Bucciantini, S, Baldi, S, Nosari, S, Marra, A, D'Anna, R, Barbaro, L, Mapelli, C, Chionna, R, Cagnacci, A, Di Carlo, C, Nappi, C, Leo, L, Pandolfo, M, Nappi, R, Tonani, S, Becorpi, A, Santilli, C, Maffei, S, Del Bravo, B, Gambacciani, M, Amorosi, A, Mantuano, R, Pasi, A, Guardianelli, F, Capozzi, A, Frantellizzi, R, Scambia, G, Villa, P, Zaza, M, Percuoco, R, Leoni, F, Dessole, S, Capobianco, G, Benedetto, C, Gallo, M, Marchesoni, D, Della Martina, M., Lello, Stefano, Sorge, Roberto, Surico, Nicola, and Nappi, Carmine

Subjects
FRAX, Bone density, Endocrinology, Diabetes and Metabolism, Osteoporosis, menopause, FRAX®, FRAX, menopause, osteoporosis, reg, Body Mass Index, osteoporosis, Fractures, Bone, Endocrinology, Quality of life, Cost of Illness, Bone Density, Risk Factors, Epidemiology, osteoporosi, Prospective Studies, Osteoporosis, Postmenopausal, Societies, Medical, Obstetrics, Obstetrics and Gynecology, Middle Aged, Algorithm, Diabetes and Metabolism, Menopause, Italy, Female, Algorithms, Human, medicine.medical_specialty, Osteoporotic Fracture, Hip Fracture, medicine, Humans, Aged, Probability, Gynecology, business.industry, Hip Fractures, Risk Factor, medicine.disease, Cost of Illne, Osteopenia, Prospective Studie, Bone Diseases, Metabolic, OSTEOPOROSIS RISK, business, Body mass index, Osteoporotic Fractures
Abstract

Osteoporosis (OP) and related fractures are well-known severe conditions affecting quality of life and life expectancy of postmenopausal women, with high economic costs in Europe. On behalf of The Italian Society of Gynecology and Obstetrics (Società Italiana di Ginecologia ed Ostetricia, SIGO), the Osteoporosis's Menopausal Epidemiological Risk Observation (O.M.E.R.O.) study, a national multicenter study on clinical risk factors of OP was organized, using FRAX® tool as a reference. Here, data from this study are presented, showing an important portion of Italian postmenopausal women affected by osteopenia/OP at high risk of fracture and the need to do prevention and/or treatment. Gynecologist can be a primary specialist in this important challenge.

Published
2015

41. Vaginal atrophy across the menopausal age: results from the ANGEL study.

Author

writing group of the ANGEL study, Cagnacci, A., Xholli, A., Sclauzero, M., Venier, M., Palma, F., and Gambacciani, M.

Subjects
CLIMACTERIC
Abstract

Objectives: This study aimed to investigate the prevalence of vaginal atrophy (VA) in women across the menopausal age.Methods: A multicenter cross-sectional investigation was performed on 747 females, 40-55 years of age, in 30 outpatient public services across the nation. The VA diagnosis was based on the combination of patient sensation of vaginal dryness, an objective sign of VA, and pH >5.Results: VA was diagnosed in 36.8% of women. Prevalence ranged from 19.2% (40-45 year olds) to 53.8% (52-55 year olds). pH >5 (37.5%) was less prevalent than isolated VA symptoms or signs. Vaginal dryness (64.0%) was the most prevalent symptom followed by dyspareunia (54.5%), itching (38.5%) burning (38.3%), and dysuria (28.9%). Prevalence of vaginal signs declined from vaginal dryness (60.3%) to vaginal thinning (54.5%), vaginal pallor (47.4%), presence of petecchiae (15.7%), and mucosa fragility (15.1%). Most signs and symptoms showed an age-related increase in frequency and intensity. VA was independently associated (R2 = 0.139; p < 0.0001) with age (odds ratio [OR] 1.08; 95% confidence interval [CI] 1.03-1.13), being in postmenopause (OR 3.45; 95% CI 2.29-5.19), and presence of vasomotor symptoms (OR 3.10; 95% CI 2.09-4.60).Conclusion: VA and its symptoms are common in women across the menopausal age. VA identification may favor early management and treatment. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. Cardiovascular disease and hormone replacement therapy

Author

Ar Genazzani and Gambacciani M

Subjects
Gynecology, medicine.medical_specialty, business.industry, Alternative medicine, Obstetrics and Gynecology, General Medicine, Disease, medicine.disease, GeneralLiterature_MISCELLANEOUS, Menopause, medicine, Position paper, Hormone replacement therapy, Intensive care medicine, business, Climacteric
Abstract

This Position Paper is based on the formal presentations and the subsequent discussions that took place at this specially convened Expert Workshop

Published
2000

44. Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy

Author

Genazzani A. R., Gambacciani M., Simoncini T., Anniverno R., Becorpi A. M., Biglia N., Brandi M. L., Guaschino S., Lello S., Massobrio M., Melis G. B., Mencacci C., Modena M. G., Nappi R. E., Pecorelli S., Petraglia F., Rosano G. M., Serra G. B., Sismondi P., Taddei S., Tonelli F., NAPPI, CARMINE, Genazzani, A. R., Gambacciani, M., Simoncini, T., Anniverno, R., Becorpi, A. M., Biglia, N., Brandi, M. L., Guaschino, S., Lello, S., Massobrio, M., Melis, G. B., Mencacci, C., Modena, M. G., Nappi, Carmine, Nappi, R. E., Pecorelli, S., Petraglia, F., Rosano, G. M., Serra, G. B., Sismondi, P., Taddei, S., and Tonelli, F.

Published
2007

45. Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study

Author

Di Donato, P, Giulini, N. A, Bacchi Modena, A, Cicchetti, G, Comitini, G, Gentile, G, Cristiani, P, Careccia, A, Esposito, E, Gualdi, F, Golinelli, S, Bergamini, E, Masellis, G, Rastelli, S, Gigli, C, Elia, A, Marchesoni, D, Sticotti, F, Del Frate, G, Zompicchiatti, C, Marino, L, Costa, M. R, Pinto, P, Dodero, D, Storace, A, Spinelli, G, Quaranta, S, Bossi, C. M, Ollago, A, Omodei, U, Vaccari, M, Luerti, M, Repetti, F, Zandonini, G, Raspagliesi, F, Dolci, F, Gambarino, G, De Pasquale, B, Polizzotti, G, Borsellino, G, Alpinelli, P, Natale, N, Colombo, D, Belloni, C, Viani, A, Cecchini, G, Vinci, G. W, Samaja, B. A, Pasinetti, E, Penotti, M, Ognissanti, F, Pesando, P, Malanetto, C, Gallo, M, Dolfin, G, Tartaglino, P, Mossotto, D, Pistoni, A, Tarani, A, Rattazzi, P. D, Rossaro, D, Campanella, M, Arisi, E, Gamper, M, Salvatores, D, Bocchin, E, Stellin, G, Meli, G, Azzini, V, Tirozzi, F, Buoso, G, Fraioli, R, Marsoni, V, Cetera, C, Sposetti, R, Candiotto, E, Pignalosa, R, Del Pup, L, Bellati, U, Angeloni, C, Buonerba, M, Garzarelli, S, Santilli, C, Mucci, M, Di Nisio, Q, Cappa, F, Pierangeli, I, Cordone, A, Falasca, L, Ferrante, D, Serra, G. B, Cirese, E, Todaro, P. A, Romanini, C, Spagnuolo, L, Lanzone, A, Donadio, C, Fabiani, M, Baldaccini, E, Votano, S, Bellardini, P, Favale, W, Monti, V, Bonomo, A, Boninfante, C. E, Pietrobattista, P, Massacesi, L, Donini, G, Del Savio, F, Palombi, L, Procaccioli, P, Romani, A, Romagnoli, G, Genazzani, A. R, Gambacciani, M, Scarselli, G, Curiel, P, De Leo, V, Melani, A, Levi D'Ancona, V, Giarrè, G, Di Gioia, E, Ceccarelli, P, Massi, G. B, Cosci, S, Gacci, G, Cascianini, A, Donati Sarti, C, Bircolotti, S, Pupita, P, Mincigrucci, M, Spadafora, A, Santeufemia, G, Marongiu, G, Lai, G. R, Lai, R, Dessole, S, D'Andrea, S. A, Coppola, Null, Chiantera, A, De Placido, Null, Arienzo, R, Pastore, A. R, Tamburrino, A, Cardone, A, Izzo, S, Tesauro, R, Pascarella, A, De Silvio, M. G, Di Prisco, L, Lauda, N, Sirimarco, F, Agrimi, C, Casarella, G, Senatore, G, Ronzini, S, Ruccia, G, De Carlo, G, Pisaturo, G, Carlomagno, F, Fasolino, A, Fiorillo, F, Sorrentino, R, Ercolano, V. B, Panariello, S, Brun, A, Tropea, P, Stigliano, C. M, Amoroso, A, Vadalà, P, Coco, A, Galati, G, Barese, G, Masciari, G, Pirillo, P, Gioffrè, T, Mastrantonio, P, Cardamone, A, D'Angelo, N, Valentino, G, Barretta, R, Ferraro, G, Ferruccio, C, Agostinelli, D, Corrado, G, Scopelliti, A, Schonauer, S, Trojano, V, Bongiovanni, F, Tinelli, F, Poddi, E. R, Scarpello, F, Colonna, L, Fischetti, G, Doria, R, Trombetta, G, Cocca, E. B, D'Amore, A, Di Masi, M, Liguori, R, Dimaggio, A, Laneve, M. R, Maolo, M. C, Gravina, G, Nacci, G, Nocera, F, Lupo, A, Giannola, C, Graziano, R, Mezzatesta, M, Vegna, G, Giannone, G, Palumbo, G, Cancellieri, F, Mondo, A, Cordopatri, A, Carrubba, M, Mazzola, V, Cincotta, L, D'Asta, S, Bono, A, Li Calsi, L, Cavallaro Nigro, S, Schilirò, S, Repici, A, Gullo, D, Orlando, A, Specchiale, F, Papotto, A, Abruzzo, Null, Basilicata, Null, Calabria, Null, Campania, Null, Emilia, Null, Romagna, Null, Giulia, Friuli Venezia, Lazio, Null, Liguria, Null, Lombardia, Null, Marche, Null, Molise, Null, Piemonte, Null, Puglia, Null, Sardegna, Null, Sicilia, Null, Toscana, Null, Adige, Trentino Alto, Umbria, Null, D'Aosta, Valle, Veneto, Null, Massacesi, A, De Aloysio, P, Campagnoli, C, Gambacciani, A, Graziottin, A, Baldi, C, Colacurci, N, Corrado Tonti, G, Parazzini, F, Chatenoud, L., COLACURCI, Nicola, Di Donato, P, Giulini, N. A, Bacchi Modena, A, Cicchetti, G, Comitini, G, Gentile, G, Cristiani, P, Careccia, A, Esposito, E, Gualdi, F, Golinelli, S, Bergamini, E, Masellis, G, Rastelli, S, Gigli, C, Elia, A, Marchesoni, D, Sticotti, F, Del Frate, G, Zompicchiatti, C, Marino, L, Costa, M. R, Pinto, P, Dodero, D, Storace, A, Spinelli, G, Quaranta, S, Bossi, C. M, Ollago, A, Omodei, U, Vaccari, M, Luerti, M, Repetti, F, Zandonini, G, Raspagliesi, F, Dolci, F, Gambarino, G, De Pasquale, B, Polizzotti, G, Borsellino, G, Alpinelli, P, Natale, N, Colombo, D, Belloni, C, Viani, A, Cecchini, G, Vinci, G. W, Samaja, B. A, Pasinetti, E, Penotti, M, Ognissanti, F, Pesando, P, Malanetto, C, Gallo, M, Dolfin, G, Tartaglino, P, Mossotto, D, Pistoni, A, Tarani, A, Rattazzi, P. D, Rossaro, D, Campanella, M, Arisi, E, Gamper, M, Salvatores, D, Bocchin, E, Stellin, G, Meli, G, Azzini, V, Tirozzi, F, Buoso, G, Fraioli, R, Marsoni, V, Cetera, C, Sposetti, R, Candiotto, E, Pignalosa, R, Del Pup, L, Bellati, U, Angeloni, C, Buonerba, M, Garzarelli, S, Santilli, C, Mucci, M, Di Nisio, Q, Cappa, F, Pierangeli, I, Cordone, A, Falasca, L, Ferrante, D, Serra, G. B, Cirese, E, Todaro, P. A, Romanini, C, Spagnuolo, L, Lanzone, A, Donadio, C, Fabiani, M, Baldaccini, E, Votano, S, Bellardini, P, Favale, W, Monti, V, Bonomo, A, Boninfante, C. E, Pietrobattista, P, Massacesi, L, Donini, G, Del Savio, F, Palombi, L, Procaccioli, P, Romani, A, Romagnoli, G, Genazzani, A. R, Gambacciani, M, Scarselli, G, Curiel, P, De Leo, V, Melani, A, Levi D'Ancona, V, Giarrè, G, Di Gioia, E, Ceccarelli, P, Massi, G. B, Cosci, S, Gacci, G, Cascianini, A, Donati Sarti, C, Bircolotti, S, Pupita, P, Mincigrucci, M, Spadafora, A, Santeufemia, G, Marongiu, G, Lai, G. R, Lai, R, Dessole, S, D'Andrea, S. A, Coppola, Null, Chiantera, A, De Placido, Null, Arienzo, R, Pastore, A. R, Tamburrino, A, Cardone, A, Colacurci, Nicola, Izzo, S, Tesauro, R, Pascarella, A, De Silvio, M. G, Di Prisco, L, Lauda, N, Sirimarco, F, Agrimi, C, Casarella, G, Senatore, G, Ronzini, S, Ruccia, G, De Carlo, G, Pisaturo, G, Carlomagno, F, Fasolino, A, Fiorillo, F, Sorrentino, R, Ercolano, V. B, Panariello, S, Brun, A, Tropea, P, Stigliano, C. M, Amoroso, A, Vadalà, P, Coco, A, Galati, G, Barese, G, Masciari, G, Pirillo, P, Gioffrè, T, Mastrantonio, P, Cardamone, A, D'Angelo, N, Valentino, G, Barretta, R, Ferraro, G, Ferruccio, C, Agostinelli, D, Corrado, G, Scopelliti, A, Schonauer, S, Trojano, V, Bongiovanni, F, Tinelli, F, Poddi, E. R, Scarpello, F, Colonna, L, Fischetti, G, Doria, R, Trombetta, G, Cocca, E. B, D'Amore, A, Di Masi, M, Liguori, R, Dimaggio, A, Laneve, M. R, Maolo, M. C, Gravina, G, Nacci, G, Nocera, F, Lupo, A, Giannola, C, Graziano, R, Mezzatesta, M, Vegna, G, Giannone, G, Palumbo, G, Cancellieri, F, Mondo, A, Cordopatri, A, Carrubba, M, Mazzola, V, Cincotta, L, D'Asta, S, Bono, A, Li Calsi, L, Cavallaro Nigro, S, Schilirò, S, Repici, A, Gullo, D, Orlando, A, Specchiale, F, Papotto, A, Abruzzo, Null, Basilicata, Null, Calabria, Null, Campania, Null, Emilia, Null, Romagna, Null, Giulia, Friuli Venezia, Lazio, Null, Liguria, Null, Lombardia, Null, Marche, Null, Molise, Null, Piemonte, Null, Puglia, Null, Sardegna, Null, Sicilia, Null, Toscana, Null, Adige, Trentino Alto, Umbria, Null, D'Aosta, Valle, Veneto, Null, Massacesi, A, De Aloysio, P, Campagnoli, C, Gambacciani, A, Graziottin, A, Baldi, C, Colacurci, N, Corrado Tonti, G, Parazzini, F, and Chatenoud, L.

Subjects
medicine.medical_specialty, Cross-sectional study, Hormone Replacement Therapy, medicine.medical_treatment, Type 2 diabetes, Motor Activity, Ambulatory Care Facilities, Age Distribution, Risk Factors, Diabetes mellitus, medicine, Odds Ratio, Humans, Obesity, Multivariate Analysi, menopausal status, Gynecology, Cross-Sectional Studie, diabetes, business.industry, Obstetrics, Risk Factor, Obstetrics and Gynecology, Hormone replacement therapy (menopause), General Medicine, Odds ratio, Middle Aged, medicine.disease, Educational Statu, Confidence interval, Menopause, Ambulatory Care Facilitie, women, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Italy, Multivariate Analysis, Educational Status, Female, business, Human
Abstract

To analyze risk factors for type 2 diabetes among women attending menopause clinics in Italy for counselling about the menopause.Women attending a network of first-level outpatient menopause clinics in Italy for general counselling about menopause or treatment of menopausal symptoms.Cross-sectional study with no exclusion criteria. Type 2 diabetes was defined according to National Diabetes Data Groups Indications and the fasting blood glucose at an oral glucose tolerance test within the previous year.Out of the 44 694 considered in this analysis, 808 had a diagnosis of diabetes type 2 (1.8%). In comparison with women aged50 years, the multivariate odds ratios (OR) of type 2 diabetes were 1.31 (95% confidence interval (CI), 0.99-1.74) for women aged 50-52 years, 1.66 (95% CI, 1.27-2.17) at 53-56 years and 2.84 (95% CI, 2.20-3.67) in women agedor = 57 years. Type 2 diabetes was less frequently reported in more educated women (OR high school/university vs. primary school = 0.44 (95% CI, 0.36-0.55)). Being overweight was associated with an increased risk of type 2 diabetes. In comparison with women reporting a low level of physical activity, the multivariate OR of type 2 diabetes was 0.67 (95% CI, 0.54-0.84) for women reporting regular physical activity. In comparison with premenopausal women, the multivariate OR of type 2 diabetes was 1.38 (95% CI, 1.03-1.84) in women with natural menopause. This finding was present also after allowing for the potential confounding effect of age. The multivariate OR of diabetes for users of hormonal replacement therapy was 0.58 (95% CI, 0.46-0.73).This large cross-sectional study suggests that postmenopausal women are at higher risk of type 2 diabetes after allowance for the effect of age. Other main determinants of risk of type 2 diabetes in women around menopause were low socioeconomic status and being overweight. Diabetes was found less frequently in those taking hormone replacement therapy.

Published
2005

46. Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy

Author

Parazzini, Fabio, Di Donato, P., Giulini, N. A., Bacchi Modena, A., Cicchetti, G., Comitini, G., Gentile, G., Cristiani, P., Careccia, A., Esposito, E., Gualdi, F., Golinelli, S., Bergamini, E., Masellis, G., Rastelli, S., Gigli, C., Elia, A., Marchesoni, D., Sticotti, F., Del Frate, G., Zompicchiatti, C., Marino, L., Costa, M. R., Pinto, P., Dodero, D., Storace, A., Spinelli, G., Quaranta, S., Bossi, C. M., Ollago, A., Omodei, U., Vaccari, M., Luerti, M., Repetti, F., Zandonini, G., Raspagliesi, F., Dolci, F., Gambarino, G., De Pasquale, B., Polizzotti, G., Borsellino, G., Alpinelli, P., Natale, N., Colombo, D., Belloni, C., Viani, A., Cecchini, G., Vinci, G. W., Samaja, B. A., Pasinetti, E., Penotti, M., Ognissanti, F., Pesando, P., Malanetto, C., Gallo, M., Dolfin, G., Tartaglino, P., Mossotto, D., Pistoni, A., Tarani, A., Rattazzi, P. D., Rossaro, D., Campanella, M., Arisi, E., Gamper, M., Salvatores, D., Bocchin, E., Stellin, G., Meli, G., Azzini, V., Tirozzi, F., Buoso, G., Fraioli, R., Marsoni, V., Cetera, C., Sposetti, R., Candiotto, E., Pignalosa, R., Del Pup, L., Bellati, U., Angeloni, C., Buonerba, M., Garzarelli, S., Santilli, C., Mucci, M., Di Nisio, Q., Cappa, F., Pierangeli, I., Cordone, A., Falasca, L., Ferrante, D., Cirese, E., Todaro, P. A., Spagnuolo, L., Lanzone, A., Donadio, C., Fabiani, M., Baldaccini, E., Votano, S., Bellardini, P., Favale, W., Monti, V., Bonomo, A., Boninfante, C. E., Pietrobattista, P., Massacesi, L., Donini, G., Del Savio, F., Palombi, L., Procaccioli, P., Romani, A., Romagnoli, G., Genazzani, A. R., Gambacciani, M., Scarselli, G., Curiel, P., De Leo, V., Melani, A., Levi D'Ancona, V., Giarrè, G., Di Gioia, E., Ceccarelli, P., Massi, G. B., Cosci, S., Gacci, G., Cascianini, A., Donati Sarti, C., Bircolotti, S., Pupita, P., Mincigrucci, M., Spadafora, A., Santeufemia, G., Marongiu, G., Lai, G. R., Lai, R., Dessole, S., D'Andrea, S. A., Coppola, Null, Chiantera, A., De Placido, Null, Arienzo, R., Pastore, A. R., Tamburrino, A., Cardone, A., Izzo, S., Tesauro, R., Pascarella, A., De Silvio, M. G., Di Prisco, L., Lauda, N., Sirimarco, F., Agrimi, C., Casarella, G., Senatore, G., Ronzini, S., Ruccia, G., De Carlo, G., Pisaturo, G., Carlomagno, F., Fasolino, A., Fiorillo, F., Sorrentino, R., Ercolano, V. B., Panariello, S., Brun, A., Tropea, P., Stigliano, C. M., Amoroso, A., Vadalà, P., Coco, A., Galati, G., Barese, G., Masciari, G., Pirillo, P., Gioffrè, T., Mastrantonio, P., Cardamone, A., D'Angelo, N., Valentino, G., Barretta, R., Ferraro, G., Ferruccio, C., Agostinelli, D., Corrado, G., Scopelliti, A., Schonauer, S., Trojano, V., Bongiovanni, F., Tinelli, F., Poddi, E. R., Scarpello, F., Colonna, L., Fischetti, G., Doria, R., Trombetta, G., Cocca, E. B., D'Amore, A., Di Mas, M., Liguori, R., Dimaggio, A., Laneve, M. R., Maolo, M. C., Gravina, G., Nacci, G., Nocera, F., Lupo, A., Giannola, C., Graziano, R., Mezzatesta, M., Vegna, G., Giannone, G., Palumbo, G., Cancellieri, F., Mondo, A., Cordopatri, A., Carrubba, M., Mazzola, V., Cincotta, L., D'Asta, S., Bono, A., Li Calsi, L., Cavallaro Nigro, S., Schilirò, S., Repici, A., Gullo, D., Orlando, A., Specchial, F., Papotto, A., Abruzzo, Angeloni, Basilicata, D'Andrea, Calabria, Stigliano, Campania, Arienzo, Emilia, Di Donato, Romagna, Giulini, Friuli Venezia Giulia, Gigli, Lazio, Todaro, Liguria, Marino, Lombardia, Luerti, Marche, Donini, Molise, Ferrante, Piemonte, Dolfin, Puglia, Poddi, Sardegna, Santeufemia, Sicilia, Nocera, Toscana, Melani, Trentino Alto Adige, Arisi, Umbria, Mincigrucci, Valle D'Aosta, Salvatores, Veneto, Bocchin, Massacesi, A., De Aloysio, P., Campagnoli, C., Gambacciani, A., Graziottin, A., Baldi, C., Colacurci, N., Corrado Tonti, G., Chatenoud, L., COLACURCI, Nicola, Parazzini, Fabio, Di Donato, P., Giulini, N. A., Bacchi Modena, A., Cicchetti, G., Comitini, G., Gentile, G., Cristiani, P., Careccia, A., Esposito, E., Gualdi, F., Golinelli, S., Bergamini, E., Masellis, G., Rastelli, S., Gigli, C., Elia, A., Marchesoni, D., Sticotti, F., Del Frate, G., Zompicchiatti, C., Marino, L., Costa, M. R., Pinto, P., Dodero, D., Storace, A., Spinelli, G., Quaranta, S., Bossi, C. M., Ollago, A., Omodei, U., Vaccari, M., Luerti, M., Repetti, F., Zandonini, G., Raspagliesi, F., Dolci, F., Gambarino, G., De Pasquale, B., Polizzotti, G., Borsellino, G., Alpinelli, P., Natale, N., Colombo, D., Belloni, C., Viani, A., Cecchini, G., Vinci, G. W., Samaja, B. A., Pasinetti, E., Penotti, M., Ognissanti, F., Pesando, P., Malanetto, C., Gallo, M., Dolfin, G., Tartaglino, P., Mossotto, D., Pistoni, A., Tarani, A., Rattazzi, P. D., Rossaro, D., Campanella, M., Arisi, E., Gamper, M., Salvatores, D., Bocchin, E., Stellin, G., Meli, G., Azzini, V., Tirozzi, F., Buoso, G., Fraioli, R., Marsoni, V., Cetera, C., Sposetti, R., Candiotto, E., Pignalosa, R., Del Pup, L., Bellati, U., Angeloni, C., Buonerba, M., Garzarelli, S., Santilli, C., Mucci, M., Di Nisio, Q., Cappa, F., Pierangeli, I., Cordone, A., Falasca, L., Ferrante, D., Cirese, E., Todaro, P. A., Spagnuolo, L., Lanzone, A., Donadio, C., Fabiani, M., Baldaccini, E., Votano, S., Bellardini, P., Favale, W., Monti, V., Bonomo, A., Boninfante, C. E., Pietrobattista, P., Massacesi, L., Donini, G., Del Savio, F., Palombi, L., Procaccioli, P., Romani, A., Romagnoli, G., Genazzani, A. R., Gambacciani, M., Scarselli, G., Curiel, P., De Leo, V., Melani, A., Levi D'Ancona, V., Giarrè, G., Di Gioia, E., Ceccarelli, P., Massi, G. B., Cosci, S., Gacci, G., Cascianini, A., Donati Sarti, C., Bircolotti, S., Pupita, P., Mincigrucci, M., Spadafora, A., Santeufemia, G., Marongiu, G., Lai, G. R., Lai, R., Dessole, S., D'Andrea, S. A., Coppola, Null, Chiantera, A., De Placido, Null, Arienzo, R., Pastore, A. R., Tamburrino, A., Cardone, A., Colacurci, Nicola, Izzo, S., Tesauro, R., Pascarella, A., De Silvio, M. G., Di Prisco, L., Lauda, N., Sirimarco, F., Agrimi, C., Casarella, G., Senatore, G., Ronzini, S., Ruccia, G., De Carlo, G., Pisaturo, G., Carlomagno, F., Fasolino, A., Fiorillo, F., Sorrentino, R., Ercolano, V. B., Panariello, S., Brun, A., Tropea, P., Stigliano, C. M., Amoroso, A., Vadalà, P., Coco, A., Galati, G., Barese, G., Masciari, G., Pirillo, P., Gioffrè, T., Mastrantonio, P., Cardamone, A., D'Angelo, N., Valentino, G., Barretta, R., Ferraro, G., Ferruccio, C., Agostinelli, D., Corrado, G., Scopelliti, A., Schonauer, S., Trojano, V., Bongiovanni, F., Tinelli, F., Poddi, E. R., Scarpello, F., Colonna, L., Fischetti, G., Doria, R., Trombetta, G., Cocca, E. B., D'Amore, A., Di Mas, M., Liguori, R., Dimaggio, A., Laneve, M. R., Maolo, M. C., Gravina, G., Nacci, G., Nocera, F., Lupo, A., Giannola, C., Graziano, R., Mezzatesta, M., Vegna, G., Giannone, G., Palumbo, G., Cancellieri, F., Mondo, A., Cordopatri, A., Carrubba, M., Mazzola, V., Cincotta, L., D'Asta, S., Bono, A., Li Calsi, L., Cavallaro Nigro, S., Schilirò, S., Repici, A., Gullo, D., Orlando, A., Specchial, F., Papotto, A., Abruzzo, Angeloni, Basilicata, D'Andrea, Calabria, Stigliano, Campania, Arienzo, Emilia, Di Donato, Romagna, Giulini, Friuli Venezia Giulia, Gigli, Lazio, Todaro, Liguria, Marino, Lombardia, Luerti, Marche, Donini, Molise, Ferrante, Piemonte, Dolfin, Puglia, Poddi, Sardegna, Santeufemia, Sicilia, Nocera, Toscana, Melani, Trentino Alto Adige, Arisi, Umbria, Mincigrucci, Valle D'Aosta, Salvatore, Veneto, Bocchin, Massacesi, A., De Aloysio, P., Campagnoli, C., Gambacciani, A., Graziottin, A., Baldi, C., Colacurci, N., Corrado Tonti, G., and Chatenoud, L.

Subjects
Aging, Epidemiology, Cross-sectional study, Marital Statu, Ambulatory Care Facilities, Body Mass Index, Age Factor, Reproductive History, Depression (differential diagnoses), Depression, Smoking, Age Factors, Headache, Obstetrics and Gynecology, Middle Aged, Menopause, Italy, Educational Status, Female, medicine.symptom, Climacteric, Human, Adult, medicine.medical_specialty, Hot Flashe, Logistic Model, Symptom, Irritability, General Biochemistry, Genetics and Molecular Biology, medicine, Humans, Aged, Cross-Sectional Studie, Marital Status, business.industry, Odds ratio, medicine.disease, Educational Statu, Diet, Ambulatory Care Facilitie, Cross-Sectional Studies, Logistic Models, Risk factors, Hot Flashes, Symptoms, Physical therapy, Risk factor, business, Body mass index, Demography
Abstract

OBJECTIVE To obtain data on correlates of climacteric symptoms in women around menopause attending menopause clinics in Italy. METHODS Since 1997 a large cross sectional study has been conducted on the characteristics of women around menopause attending a network of first level menopause outpatient's clinics in Italy. A total of 66,501 (mean age 54.4 years) women are considered in the present paper. RESULTS The odds ratios of moderate and severe hot flashes/night sweats were lower in more educated women and (for severe symptoms only) in women reporting regular physical activity. Depression, difficulty to sleep, forgetfulness and irritability tended to be less frequent in more educated women and (depression only) in women reporting regular physical activity. Parous women reported more frequently these symptoms. CONCLUSIONS This large study confirms in Southern European population that low education, body mass index and low physical activity are associated with climacteric symptoms. Parous women are at greater risk of psychological symptoms.

Published
2005

48. Empfehlungen zur postmenopausalen Hormontherapie

Author

Pines, A, Sturdee, D, Birkhäuser, MH, Gambacciani, M, and Panay, N

Subjects
Postmenopause, hormonal therapy, post-menopause, Hormontherapie, Menopause, lcsh:Gynecology and obstetrics, lcsh:RG1-991
Published
2007

Catalog

Books, media, physical & digital resources
See catalog results